AKTX Akari Therapeutics Plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1541157 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-86.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-146.3%
ROA-71.8%
ROIC (approx.)-140.0%
Asset turnover—
Leverage & solvency
Liabilities / assets52.2%
Debt / equity0.00x
Current ratio0.48x
Interest coverage-282.65x
Cash quality & payout
Operating cash flow / net income0.44x
Accruals ratio-40.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $2.81M | $6.98M | $5.45M | $9.56M | $9.13M |
| SG&A expense | $9.28M | $9.66M | $11.36M | $13.53M | $8.08M |
| Operating income | -$17.27M | -$21.64M | -$16.81M | -$23.09M | -$17.21M |
| Interest expense | $100,000 | $244,000 | — | — | — |
| Pretax income | -$18.30M | -$19.79M | -$10.01M | -$17,748 | -$17.42M |
| Income tax | -$1.00M | $0 | $0 | $0 | $0 |
| Net income | -$17.30M | -$19.79M | -$10.01M | -$17.75M | -$17.42M |
| EBITDA | — | -$21.63M | -$16.80M | -$23.08M | -$17.21M |
| EPS (basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 67.33B | 23.89B | 9.79B | 6.24B | 4.29B |
| Balance sheet | |||||
| Cash & equivalents | $5.20M | $2.66M | $3.85M | $13.25M | $9.36M |
| Current assets | $5.46M | $2.95M | $4.34M | $13.81M | $11.63M |
| PP&E, net | — | — | — | $0 | $0 |
| Goodwill | $8.43M | $8.43M | — | — | — |
| Intangibles | — | — | $14,000 | $17,000 | $22,929 |
| Total assets | $47.89M | $50.56M | $4.36M | $13.83M | $11.65M |
| Current liabilities | $12.35M | $19.91M | $4.58M | — | — |
| Total liabilities | $19.56M | $28.33M | $4.58M | $12.04M | $6.09M |
| Shareholders' equity | $28.33M | $22.23M | -$229,000 | $1.79M | $5.55M |
| Shares outstanding | 90.54B | 53.19B | 13.23B | 7.44B | 4.76B |
| Cash flow statement | |||||
| Operating cash flow | -$10.57M | -$12.55M | -$16.43M | -$21.50M | -$18.85M |
| Investing cash flow | — | $382,000 | — | — | — |
| Financing cash flow | $13.17M | $10.99M | $7.02M | $25.29M | $14.29M |
| Depreciation & amortization | — | $14,000 | $4,000 | $4,000 | $4,126 |
| Stock-based compensation | $2.89M | $2.25M | $1.15M | $735,000 | $314,650 |
Free plan shows the latest 5 periods; Pro shows all 20 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.